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A precision medicine approach to haematological 
malignancies
In The Lancet Haematology, Berend Snijder and colleagues1 
report interim results of their study evaluating the effect 
of ex-vivo drug sensitivity screening on the treatment of 
patients with refractory haematological malignancies. 
Using an automated immunofluorescence microscopy-
based platform named pharmacoscopy, the authors 
prospectively evaluated 48 patients with various 
haematological malignancies, 17 of whom received 
treatment guided by this approach. Given the inherent 
heterogeneity of this cohort, the investigators opted 
to compare the benefit of pharmacoscopy-guided 
treatment to the effect of previous treatments in the 
same patient. They observed a marked improvement in 
progression-free survival with pharmacoscopy-guided 
intervention with almost half of the patients (eight of 
17 patients) still disease free at their last follow-up visit, 
providing evidence for the promise of drug-response 
profiling in haemato-oncology.
Most precision medicine initiatives have focused on 
genomics, but few have included functional assays.2 
Phenotypic screening approaches could contribute im-
portant information to improve the selection of the 
right drug for the right patient at the right time in their 
treatment. First proof-of-concept data was obtained with 
functional screens using kinase inhibitors,3 leading to a 
clinical trial for targeted therapy of relapsed acute myeloid 
leukaemia that is still ongoing (NCT01620216). In line 
with the results of Snijder and colleagues, a landmark 
paper4 showed how drug profiling predicts activity and 
resistance to drugs in patients. Both platforms detect 
drug activity in cell cultures with luminescent assays. This 
format has the advantages of full automation and high 
throughput, but does not deliver functional information 
at the single-cell level. To address intrapatient hetero-
geneity of malignant and normal cells, and to take 
advantage of more complex coculture systems, many 
investigators are now turning to automated, microscopic 
imaging technology. Such minimally invasive protocols 
enable highly informative drug-response profiling in 
stroma coculture systems that can maintain leukaemia 
and multiple myeloma cells for a longer time, expanding 
the screening capabilities of patient samples.5–7 Snijder 
and colleagues now show that it is possible to do 
multiparametric, image-based, immunophenotypic 
cytometry to reliably distinguish malignant cells from 
normal blood cells in a high-content screening context. 
In their seminal paper,8 the investigators showed how 
this approach can detect phenotypes across several 
cellular compartments, quantifying, for example, T-cell 
engagement by the bispecific, CD19-directed, T-cell 
engager blinatumomab in patient samples. 
The idea of testing cellular drug resistance to assist 
clinical decision making is not new. Short-term 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays to determine responses to 
conventional antileukaemic drugs almost three decades 
ago did not translate into clinical practice.9 Why would 
the revival of ex-vivo drug testing make a difference 
today? Studies4,5,8,10 from Snijder and colleagues and 
others provide strong elements of a response. Testing 
a sufficient number of therapeutic agents across 
functional classes detects highly informative, but indivi-
dually heterogeneous, drug-response patterns for 
each disease. Valuable information can be gained with 
respect to sensitivity to functional classes of agents 
and drug resistance, which underscores the underlying 
complexity and the need for more personalised ap-
proaches to treatment. The approach will become more 
powerful as functional information is interpreted in 
relation to data from a growing number of patients 
with sufficient coverage for each disease. This principle 
is highlighted by a study10 showing that drug responses 
can partition chronic lymphocytic leukaemia in clinically 
relevant subgroups according to Bruton’s tyrosine kinase 
(BTK) and mechanistic target of rapamycin (mTOR) 
dependencies. Importantly, relevant phenotypes can be 
detected that would not have been predicted by genomic 
information. To build such a growing database of 
knowledge will require substantial efforts to harmonise 
output from different platforms and solve logistical 
bottlenecks for multicentric trials.
Finally, this study provides stimulating insights for 
future clinical trial design. Staber and colleagues have 
chosen the pragmatic single institutional approach 
for their interventional study of relapsed or refractory 
acute leukaemia (NCT03096821). Their study design 
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provides the highest possible flexibility for experimental 
treatment including combination of different modal-
ities in the best interest of their patients. This trial 
pilots several relevant clinical scenarios that will have an 
impact on the design of future trials, for example data-
guided combination of targeted agents with antibody-
based therapies for lymphoid malignancies. As Snijder 
and colleagues point out, larger studies should focus on 
specific disease entities to capture the full potential of 
phenotypic screening. In my view, phenotypic screening 
should also be explored in frontline therapy with the 
aim to reduce unnecessary exposure to toxic agents and 
improve responses in selected subgroups in the future. 
One could envision trial designs that allow for modular 
substitution of treatment elements and randomisation 
of combination therapy including immunotherapy. 
The jury is still out, but systematic exploration of such 
functional approaches should be intensively promoted 
to demonstrate their potential in precision oncology.
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